Decoy Therapeutics awarded Chief Business Officer Marschel Peter Klaus 3,900 shares at $0 per share on Aug. 31, 2026. For investors, the transaction establishes Klaus’s disclosed post-award ownership at 3,900 Decoy Therapeutics shares, connecting the executive award with his resulting Equity position.
Key Highlights
- The transaction was dated Aug. 31, 2026.
- The shares carried an award price of $0 per share.
- Marschel Peter Klaus held 3,900 Decoy Therapeutics shares after the transaction.
Decoy Therapeutics Inc. (NASDAQ: DCOY) awarded 3,900 shares to Marschel Peter Klaus, its chief business officer, at $0 per share. The transaction dated Aug. 31, 2026, left Klaus with 3,900 Decoy Therapeutics shares.
Zero-Cost Award Dated Aug. 31, 2026
The equity award covered 3,900 shares of Decoy Therapeutics stock. The transaction date was Aug. 31, 2026. Klaus’s ownership following the award was 3,900 shares. The award and the resulting ownership figure are both tied to Marschel Peter Klaus.
FAQs
Q: How many shares did Decoy Therapeutics award Marschel Peter Klaus?
A: Decoy Therapeutics awarded Chief Business Officer Marschel Peter Klaus 3,900 shares. The transaction was dated Aug. 31, 2026, and the price was $0 per share.
Q: What was the impact of the DCOY stock award on Klaus’s holdings?
A: The DCOY stock award left Marschel Peter Klaus with 3,900 Decoy Therapeutics shares. Klaus is identified as the company’s chief business officer.
Q: When did the Decoy Therapeutics executive share award occur?
A: The Decoy Therapeutics share award to Marschel Peter Klaus occurred on Aug. 31, 2026. The transaction involved 3,900 shares issued at $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.